Renal Cancer


Advances in Immunotherapy Starting to Define Cancer Treatment (March 9, 2017)

T cell lymphocyte with receptors to kill cancer cell in cancer immunotherapy A handful of drugs recently developed and approved by the United States Food and Drug Administration are expanding the emerging... Continue Reading

Dalantercept- Inlyta Shows Promise for Renal Cell Cancer (March 1, 2017)

The combination of Inlyta (axitinib) and dalantercept, an activin receptor–like kinase 1 (ALK1) signaling inhibitor appears promising in the treatment of advanced renal cell carcinoma (RCC) according... Continue Reading

New Drug Beats Standard Therapy in Advanced Kidney Cancer (December 13, 2016)

An experimental kidney cancer drug outperformed the standard first-line therapy for patients with metastatic disease who are considered at risk for poorer than average outcomes, according to results of... Continue Reading

Cabometyx™ Improves Time to Cancer Progression as Initial Therapy in Kidney Cancer (December 5, 2016)

The agent Cabometyx™ (cabozantinib) improves anti-cancer responses and time to cancer progression compared to Sutent® (sunitinib) when used as initial therapy for advanced kidney cancer. These results... Continue Reading

Obesity Linked to Improved Survival in Kidney Cancer (September 12, 2016)

Obesity almost always increases cancer risk and worsens outcomes, but researchers led by scientists at Dana-Farber Cancer Institute report that overweight patients with advanced kidney cancer had significantly... Continue Reading

Surgery Can Lengthen Survival of Metastatic Kidney Cancer Patients Treated with Targeted Therapies, Study Finds (July 6, 2016)

Surgery to remove a cancerous kidney can often lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer, but only about three in 10 such patients undergo the procedure, according... Continue Reading

Lenvima® Approved for Kidney Cancer (May 24, 2016)

The United States Food and Drug Administration (FDA) has approved Lenvima® (lenvatinib) for the treatment of kidney cancer. The approval is for patients with advanced renal cell carcinoma who have received... Continue Reading

Cabometyx™ Approved for Kidney Cancer (May 10, 2016)

The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx™ (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients... Continue Reading

Worth a Look: It’s Kidney Cancer Awareness Month (March 18, 2016)

The kidneys are two (or one) bean-shaped organs about the size of a fist and are located near the middle of your back on either side of your spine and just below the rib cage. They are vital organs; you... Continue Reading

FDA Approves Opdivo for Renal Cell Carcinoma (November 25, 2015)

The FDA granted approval to nivolumab (Opdivo) for patients with renal cell carcinoma. Opdivo, a PD-1 inhibitor, was previously approved for the treatment of melanoma whose tumors express the BRAF V600... Continue Reading

COMETRIQ® Improves Progression-Free Survival in Kidney Cancer (October 15, 2015)

According to a recently published study in the New England Journal of Medicine, the targeted agent, COMETRIQ® (cabozantinib), significantly improves the time to cancer progression and survival compared... Continue Reading

Opdivo® Improves Survival in Kidney Cancer (October 12, 2015)

The immunotherapy agent, Opdivo® (nivolumab), improves survival in kidney cancer compared to the standard treatment, Afinitor® (everolimus). These results were recently published in the New England Journal... Continue Reading

FDA Grants Breakthrough Therapy Designation to LENVIMA™ for the Potential Treatment of Metastatic Renal Cell Carcinoma (August 3, 2015)

Eisai Inc. has announced that the U.S. Food and Drug Administration (FDA) granted LENVIMA™ (lenvatinib), the company’s multiple receptor tyrosine kinase inhibitor, Breakthrough Therapy designation... Continue Reading

Study of Opdivo® versus Afinitor® Stopped Early when Opdivo Demonstrated Better Survival (July 29, 2015)

Patients with advanced or metastatic kidney cancer who are treated with Opdivo® (nivolumab) have better overall survival than those treated with Afinitor® (everolimus), according to findings from a Phase... Continue Reading

National Kidney Cancer Awareness Month on CancerConnect (March 6, 2015)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of kidney cancer educational programs for national kidney cancer awareness month. As the month of March brings kidney... Continue Reading

OMNI-Connect Gets National Recognition as Valuable Social Media Solution in Medicine (August 13, 2014)

Fort Worth TX/Sun Valley ID – OMNI Health Media announces national recognition of its online support communities, TheGIConnection,TheRAConnection, and Cancer Connect, as valuable resources for... Continue Reading

Genomic Health Demonstrates the Importance of Utilizing Multiple Biological Pathways to Predict Tumor Behavior in Prostate and Renal Cancers (June 9, 2014)

REDWOOD CITY, Calif., June 3, 2014 /PRNewswire/ — Genomic Health, Inc. (Nasdaq: GHDX) today announced results of two studies demonstrating the ability of its Oncotype DX® test and a new 16-gene... Continue Reading

Marriage May Have a Protective Effect for Cancer Patients (December 17, 2013)

Social support may have a significant impact on cancer detection, treatment, and survival, according to the results of a study published in the Journal of Clinical Oncology. The study showed that married... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS